Calliditas Therapeutics winner of the SwedenBIO Award 2020

For the 14th year in a row, SwedenBIO awards the prize to a company that has distinguished itself through achievements in research and development, business development, growth and also contributed to social benefit.

Calliditas Therapeutics has purposefully developed its drug candidate Nefecon for chronic kidney inflammation (IgA nephropathy) and recently presented positive results from a pivotal Phase 3 study.

– This year’s winners have shown impressive professionalism and perseverance in developing a completely new treatment for patients with chronic kidney inflammation who currently lack effective therapy. With positive phase 3 results in place, we are now preparing a registration application and a market introduction in the US,” comments Lars Adlersson, chairman of SwedenBIO and representative of the jury.

Calliditas has started preparations to commercialize Nefecon in the US market and has attracted a Chinese partner within the framework of one of the largest Swedish-Chinese collaboration agreements for a pharmaceutical project to date.

The company’s success has attracted considerable attention from both Nordic and international investors, and since its IPO in Sweden in 2018, the company’s market value has tripled. In 2020, a parallel listing of the share was made on the Nasdaq Global Select Market in the US.

– We are very honored to receive this recognition. Calliditas has had a very exciting journey so far as pioneers in the development of treatment for IgA nephropathy and we look forward to building Calliditas for the future and developing additional therapies in niche diseases,” said Renée Aguiar-Lucander, CEO of Calliditas Therapeutics.

IgA nephropathy
IgA nephropathy is a disease that leads to terminal kidney failure in nearly half of those affected. There are currently no approved drugs for these patients and many have to undergo dialysis or kidney transplantation. It greatly reduces the quality of life and leads to high healthcare costs.

Nominees
Of the nominated companies for the SwedenBIO Award 2020, the jury selected five finalists: Calliditas Therapeutics, Cellink, Cobra Biologics, Hansa Biopharma and Kancera.

SwedenBIO Award
The SwedenBIO Award is the industry’s own award and is presented to an exemplary company that has distinguished itself and contributed to positive attention for the industry. In addition to the honor, the winner will receive a travel prize and two delegate seats to the Nordic Life Science Days 20-23 September 2021(www.nlsdays.com). The prize is awarded jointly with HealthCap.

The jury
The winner is chosen by the SwedenBIO board: Lars Adlersson, Adlersson Heath, Lotta Ljungqvist, Testa Center-Cytiva, Carl-Johan Spak, Recipharm, Christine Wesström, Sobi, Kertin Falck, Pfizer, Magnus Björsne, AstraZeneca BioVentureHub, Per Samuelsson, HealthCap, and Sarah Fredriksson, AQILION.

Contact
Lars Adlersson, Chairman of SwedenBIO, lars.adlersson@swedenbio.se, 0706 66 62 36.